Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.
10.3347/kjp.2006.44.3.221
- Author:
Srivicha KRUDSOOD
1
;
Polrat WILAIRATANA
;
Noppadon TANGPUKDEE
;
Kobsiri CHALERMRUT
;
Siripun SRIVILAIRIT
;
Vipa THANACHARTWET
;
Sant MUANGNOICHAROEN
;
Natthanej LUPLERTLOP
;
Gary M BRITTENHAM
;
Sornchai LOOAREESUWAN
Author Information
1. Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand. tmpwl@mahidol.ac.th
- Publication Type:Original Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Plasmodium vivax;
vivax malaria;
elubaquine;
bulaquine;
safety;
tolerability;
Thailand
- MeSH:
Thailand;
Prospective Studies;
Primaquine/adverse effects/*analogs & derivatives/therapeutic use;
*Plasmodium vivax;
Middle Aged;
Male;
Malaria, Vivax/*drug therapy;
Humans;
Female;
Chloroquine/therapeutic use;
Antimalarials/*adverse effects/therapeutic use;
Animals;
Adult;
Adolescent
- From:The Korean Journal of Parasitology
2006;44(3):221-228
- CountryRepublic of Korea
- Language:English
-
Abstract:
We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.
